On the weekend the FDA rejected $SMMT drug. PFS win, but OS missed: HR 0.79, p=0.057. Not enough.
48 hours later Sellas $SLS hits OS outright in AML:
24.0 vs 14.7 months median survival
HR 0.59, p=0.035
The catch: 126 patients, 80 deaths. A small trial, but on the right endpoint.
The FDA just told everyone which endpoint it pays for. Sellas plans its BLA for 1H 2027
1
324
Quebecor’s $QBR.B.TO offer is worth about C$19.45 per share, valuing Telus $T.TO at around C$31 billion ($21.7 billion). That would be a 60% premium to Friday’s closing share price.
209
CANACCORD $CF.TO ENTERS INTO AGREEMENT TO BE TAKEN PRIVATE BY CHAIRMAN AND CEO DAN DAVIAU
Shareholders to receive aggregate consideration of $15.27 per common share comprised of $7.45, plus proceeds of £4.15
Altius Minerals to Acquire TNR Gold in C$122 Million Cash
The deal represents an implied consideration of about C$0.48 per TNR share, a 60% premium to the stock's closing price on Tuesday, which is listed on the TSX Venture Exchange
Congrats @YellowLabLife on surfacing the value.
Mirum $MIRM brelovitug in hepatitis delta. Second Phase 3 win in two months.
AZURE-4 at week 24:
300 mg weekly: 59% hit the combined endpoint
900 mg monthly: 44%
Delayed-treatment arm: 0%
The real story is the 108-week data in cirrhosis patients, with 100% virologic response and 100% ALT normalization (only 15 patients).
Half of these patients are cirrhotic and there's no approved HDV drug in the US. BLA is planned for H1 2027, and Vir is chasing the same market.
90
Faeth Thera $FTH printed "positive" Phase 2 data this morning. Stock went from +18% to -22% premarket.
Headline: 33% confirmed response (12/36). 44% in PIK3CA-mutant (7/16).
Fine print: single-arm, no control. And 64% grade 3+ treatment-related side effects, under a release that says "generally well tolerated."
Next up: they want a Phase 3. The market already voted on the toxicity given it finished down 42%.
164
Zura Bio $ZURA down ~68% premarket after tibulizumab missed its Phase 2 in hidradenitis suppurativa.
AN count reduction at week 16:
300 mg: 56.0%
150 mg: 58.1%
Placebo: 52.5%
That's the story. The drug didn't fail to move patients. Placebo moved them almost as much.
HS keeps punishing trials with huge placebo responses. If you can't separate signal from noise in who responds, you need a bigger trial or a smarter one.
2
425
Servier’s $1.55B bet for Edgewise's sevasemten just backfired.
This week the 175-patient, 18-month Becker muscular dystrophy pivotal missed its primary endpoint and every secondary.
A biomarker win isn't a functional win. $EWTX
The warning was in the Phase 2. It won on a biomarker (creatine kinase) but never hit significance on the same functional scale the pivotal used.
222











